Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilan...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2168947 |